Celldex Therapeutics (CLDX) Reaches New 12-Month Low at $0.28

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $0.28 and last traded at $0.28, with a volume of 1342309 shares trading hands. The stock had previously closed at $0.29.

Several analysts have recently issued reports on CLDX shares. HC Wainwright set a $2.00 price target on shares of Celldex Therapeutics and gave the company a “buy” rating in a research report on Monday, November 19th. Cowen reissued a “hold” rating on shares of Celldex Therapeutics in a research report on Thursday, August 9th. Finally, Jefferies Financial Group reissued a “hold” rating on shares of Celldex Therapeutics in a research report on Friday, August 10th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the company. Celldex Therapeutics has a consensus rating of “Hold” and an average price target of $3.75.

The company has a market cap of $51.50 million, a P/E ratio of -0.35 and a beta of 2.60.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.07. The company had revenue of $0.94 million during the quarter, compared to analysts’ expectations of $2.08 million. Celldex Therapeutics had a negative net margin of 1,296.96% and a negative return on equity of 51.88%. As a group, sell-side analysts anticipate that Celldex Therapeutics, Inc. will post -0.39 EPS for the current year.

A number of large investors have recently modified their holdings of CLDX. LMR Partners LLP purchased a new position in Celldex Therapeutics during the second quarter valued at approximately $206,000. GSA Capital Partners LLP purchased a new position in Celldex Therapeutics during the second quarter valued at approximately $322,000. Paloma Partners Management Co grew its stake in Celldex Therapeutics by 5,357.8% during the second quarter. Paloma Partners Management Co now owns 640,799 shares of the biopharmaceutical company’s stock valued at $323,000 after acquiring an additional 629,058 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in Celldex Therapeutics by 27.7% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 900,185 shares of the biopharmaceutical company’s stock valued at $453,000 after acquiring an additional 195,147 shares in the last quarter. Finally, Acadian Asset Management LLC grew its stake in Celldex Therapeutics by 378.4% during the second quarter. Acadian Asset Management LLC now owns 1,157,880 shares of the biopharmaceutical company’s stock valued at $583,000 after acquiring an additional 915,863 shares in the last quarter. 27.78% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Celldex Therapeutics (CLDX) Reaches New 12-Month Low at $0.28” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.com-unik.info/2018/12/05/celldex-therapeutics-cldx-reaches-new-12-month-low-at-0-28.html.

Celldex Therapeutics Company Profile (NASDAQ:CLDX)

Celldex Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma.

See Also: Asset Allocation and Your Retirement

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit